Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 5030 (117th)

DIVERSE Trials Act

referredUnited States· United States Congress· EN

Introduced

13 August 2021

Last action

16 August 2021 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Ruiz, Raul [D-CA-25], Rep. Bucshon, Larry [R-IN-8], Rep. Salazar, Maria Elvira [R-FL-27], Rep. Rush, Bobby L. [D-IL-1], Rep. Ross, Deborah K. [D-NC-2], Rep. Higgins, Brian [D-NY-26], Rep. Soto, Darren [D-FL-9], Rep. Bonamici, Suzanne [D-OR-1], Rep. Mfume, Kweisi [D-MD-7], Rep. Larson, John B. [D-CT-1], Rep. Brownley, Julia [D-CA-26], Rep. Carbajal, Salud O. [D-CA-24], Rep. Napolitano, Grace F. [D-CA-32], Rep. Evans, Dwight [D-PA-3], Rep. Beatty, Joyce [D-OH-3], Rep. Johnson, Eddie Bernice [D-TX-30], Sen. Blunt Rochester, Lisa [D-DE], Rep. Rutherford, John H. [R-FL-5], Rep. Jayapal, Pramila [D-WA-7], Kaiali'i Kahele, Rep. Cleaver, Emanuel [D-MO-5], Rep. Blumenauer, Earl [D-OR-3], Rep. Jacobs, Sara [D-CA-51], Rep. Harder, Josh [D-CA-9], Rep. Davids, Sharice [D-KS-3], Rep. Lynch, Stephen F. [D-MA-8], Sen. Welch, Peter [D-VT], Rep. Langevin, James R. [D-RI-2], Rep. Posey, Bill [R-FL-8], Rep. Swalwell, Eric [D-CA-15], Rep. Ryan, Tim [D-OH-13], Rep. Sherrill, Mikie [D-NJ-11], Rep. Quigley, Mike [D-IL-5], Rep. Kilmer, Derek [D-WA-6], Rep. Kuster, Ann M. [D-NH-2], Rep. Cherfilus-McCormick, Sheila [D-FL-20], Rep. Khanna, Ro [D-CA-17], Rep. Matsui, Doris O. [D-CA-7], Rep. McGovern, James P. [D-MA-2], Rep. Omar, Ilhan [D-MN-5], Rep. Underwood, Lauren [D-IL-14], Rep. Cicilline, David N. [D-RI-1], Rep. Lawrence, Brenda L. [D-MI-14], Rep. Levin, Mike [D-CA-49], Rep. O'Halleran, Tom [D-AZ-1], Rep. Kildee, Daniel T. [D-MI-5], Rep. Pappas, Chris [D-NH-1], Rep. Cohen, Steve [D-TN-9]

Subjects

Healthcare, Education

Source updated

5 December 2025

Healthcare · Education

Official sourceDownload fileView documentsShare

Summary

Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act or the DIVERSE Trials Act This bill requires activities to increase diversity in clinical trials. It also expands reporting by laboratories that test for and diagnose COVID-19 and requires a study on data collection and data sharing during public health emergencies. Specifically, the Food and Drug Administration (FDA) must issue guidance on decentralized clinical trials to promote meaningful demographic and geographic diversity in patient engagement, enrollment, and participation. Decentralized clinical trials include those executed through telemedicine or other digital technologies to allow for the remote collection and assessment of clinical trial data. The FDA may also work with foreign regulators to harmonize international regulations governing decentralized clinical trials and the use of digital health technology. In addition, the Department of Health and Human Services (HHS) may support community education, outreach, and recruitment activities for clinical trials of treatments for conditions that disproportionately impact populations underrepresented in clinical trials. The bill also specifies that drug or device manufacturers may provide, subject to some limits, free digital health technologies and other remuneration to patients in approved clinical trials without violating laws that address fraud and abuse in federal programs. Furthermore, laboratories that test for and diagnose COVID-19 must report additional demographic data, including information about social determinants of health. HHS must also contract with the National Academy of Medicine to study and propose a design for an interoperable platform to facilitate data sharing during public health emergencies.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 13 August 2021

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  2. 13 August 2021

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  3. 13 August 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 13 August 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 16 August 2021

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 13 August 2021

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 13 August 2021

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 13 August 2021

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 57 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.